NEW YORK (GenomeWeb News) — Biosite today disclosed that it “currently intends” to accept Inverness Medical Innovations’ bid to acquire it, and plans to terminate an earlier offer made by Beckman Coulter.

 

In the latest, and what appears to be final, twist of the ongoing battle for Biosite, the company said that a binding offer it recently received from Inverness is “superior” to Beckman Coulter’s bid as defined in the existing merger agreement between Beckman Coulter and Biosite.